Vir Biotechnology Inc (VIR) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Vir Biotechnology Inc (VIR) has a cash flow conversion efficiency ratio of -0.009x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-9.06 Million) by net assets ($982.49 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see VIR market cap overview for the company's overall valuation and market capitalisation.
Vir Biotechnology Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Vir Biotechnology Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Vir Biotechnology Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Vir Biotechnology Inc ranked by their cash flow conversion efficiency. Explore earnings quality score of Vir Biotechnology Inc to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Monadelphous Group Ltd
F:8MP
|
0.043x |
|
BEML Limited
NSE:BEML
|
-0.087x |
|
Guangdong Jia Yuan Technology Co Ltd
SHG:688388
|
0.006x |
|
Live Oak Bancshares, Inc.
NYSE:LOB
|
0.090x |
|
Cyrela Brazil Realty S.A. Empreendimentos e Participações
SA:CYRE3
|
0.029x |
|
China-Singapore Suzhou Industrial Park Development Group Co Ltd
SHG:601512
|
0.010x |
|
ZAI LAB LTD0000006
F:1ZLB
|
-0.018x |
|
Shaanxi Ligeance Mineral Resources Co Ltd
SHE:000697
|
0.002x |
Annual Cash Flow Conversion Efficiency for Vir Biotechnology Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Vir Biotechnology Inc from 2017 to 2025. View Vir Biotechnology Inc stock quote for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $765.28 Million | $-391.78 Million | -0.512x | -31.94% |
| 2024-12-31 | $1.15 Billion | $-446.35 Million | -0.388x | +20.77% |
| 2023-12-31 | $1.59 Billion | $-778.78 Million | -0.490x | -161.18% |
| 2022-12-31 | $2.08 Billion | $1.66 Billion | 0.800x | +2508.30% |
| 2021-12-31 | $1.43 Billion | $-47.59 Million | -0.033x | +87.52% |
| 2020-12-31 | $716.85 Million | $-190.94 Million | -0.266x | +12.89% |
| 2019-12-31 | $423.94 Million | $-129.63 Million | -0.306x | -158.23% |
| 2018-12-31 | $-179.18 Million | $-94.10 Million | 0.525x | -45.48% |
| 2017-12-31 | $-68.92 Million | $-66.38 Million | 0.963x | -- |
About Vir Biotechnology Inc
Vir Biotechnology, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutic products to treat and prevent serious infectious diseases in the United States and internationally. Its clinical development pipeline consists of product investigational therapies targeting hepatitis delta virus (HDV) and other solid tumors. The company's preclinical candidates include those ta… Read more